CRIS Current Research Information System

BRIGNOLA, CORRADO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 684
EU - Europa 528
AS - Asia 152
AF - Africa 41
OC - Oceania 2
Totale 1.407
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 680
SE - Svezia 200
SG - Singapore 99
DE - Germania 90
IE - Irlanda 79
GB - Regno Unito 49
IT - Italia 38
BG - Bulgaria 35
CI - Costa d'Avorio 21
JO - Giordania 21
TG - Togo 18
CH - Svizzera 17
IN - India 16
IR - Iran 10
FI - Finlandia 9
FR - Francia 7
CA - Canada 4
CN - Cina 3
JP - Giappone 3
AU - Australia 2
RO - Romania 2
BE - Belgio 1
NG - Nigeria 1
RU - Federazione Russa 1
ZA - Sudafrica 1
Totale 1.407
Salva come PNG Salva come JPEG
Città #
Chandler 182
Singapore 80
Dublin 79
Princeton 72
Ashburn 71
Southend 46
Berlin 35
Sofia 31
Abidjan 21
Amman 21
Lomé 18
Bern 17
Santa Clara 16
Fairfield 10
Milan 10
Helsinki 8
Washington 8
Frankfurt am Main 6
Houston 6
Olalla 6
San Diego 6
Woodbridge 6
Bologna 5
Los Angeles 5
New York 5
Nuremberg 5
Perugia 5
Turin 5
Chicago 4
Cambridge 3
Guangzhou 3
Paris 3
Zanjan 3
Andover 2
Augusta 2
Boardman 2
Bühl 2
Hamburg 2
Leawood 2
Montreal 2
Piacenza 2
Prato 2
Prescot 2
Redmond 2
Sacramento 2
Seattle 2
Ann Arbor 1
Baia Mare 1
Boydton 1
Bremen 1
Brussels 1
Buffalo 1
Büdelsdorf 1
Cedar Knolls 1
Council Bluffs 1
Fort Worth 1
Henderson 1
Lagos 1
Lappeenranta 1
Naples 1
Napoli 1
Pisa 1
Pune 1
Raleigh 1
San Lazzaro di Savena 1
Sebokeng 1
Springfield 1
Suffern 1
Toronto 1
Torre Del Greco 1
Wilmington 1
Winnipeg 1
Totale 853
Salva come PNG Salva come JPEG
Nome #
5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema 86
5-Aminosalicylic acid suppositories in the management of ulcerative colitis 73
5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? 61
Analysis of biological variables in Crohn's disease [4] 54
[Abdominal scintigraphy with leukocytes marked with indium-111 in Crohn disease: clinical importance and prognostic usefulness] 54
5-Aminosalicylic acid for the treatment of inflammatory bowel diseases 51
A Possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: Interaction with oxygen free radicals 50
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion 48
Bioavailability of single and multiple doses of a new oral formulation of 5‐ASA in patients with inflammatory bowel disease and healthy volunteers 48
Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis 46
Changes in splanchnic hemodynamics in inflammatory bowel disease non-invasive assessment by doppler ultrasound flowmetry 45
Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients 42
Influence of steroid treatment's duration in patients with active Crohn's disease 42
Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis 42
Macrophage subpopulations in pouchitis 41
Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission 40
Bronchopulmonary involvement in ulcerative colitis 39
Scavenger effect of sulphasalazine (SASP), 5-aminosalicylic acid (5-ASA), and olsalazine (OAZ) (I) 38
Role of rectal formulations: Enemas 37
Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils 36
Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation 35
Optimum dosage of 5-Aminosalicylic acid as rectal enemas in patients with active ulcerative colitis 35
Interleukin 1 in ulcerative colitis 35
Requirements for the use of intestinal action antibiotics in the treatment of ulcerative colitis 35
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis 34
Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation - A double-blind placebo controlled trial 34
Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients 33
Interleukin 1 beta (IL-1 beta) release from fresh and cultured colonic mucosa in patients with ulcerative colitis (UC) 33
Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease 32
Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis 31
Short report: zinc sulphate supplementation corrects abnormal erythrocyte membrane long‐chain fatty acid composition in patients with Crohn's disease 30
Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis 30
Systemic availability of 5-aminosalicylic acid: Comparison of delayed release and an azo-bond preparation 25
Pentasa in maintenance treatment of ulcerative colitis 24
Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis 23
Mucosal concentrations of interleukin-1β, interleukin-6, interleukin-8, and tumor necrosis factor-α in pelvic ileal pouches 21
Factors affecting recurrence in Crohn's disease: Results of a prospective audit 3
Totale 1.466
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.328
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.328
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022386 0 0 0 0 0 0 0 0 133 52 153 48
2022/2023752 72 114 69 48 45 59 21 59 146 22 34 63
2023/2024185 13 33 17 16 18 49 3 11 4 16 5 0
2024/2025143 49 79 15 0 0 0 0 0 0 0 0 0
Totale 1.466